Video claim watch
National reporting on prescribing and access to an unapproved investigational drug shows how retatrutide is entering mainstream safety coverage.
Transcript review
Reviewed Jul 12, 2026. Next review Aug 12, 2026.
condensed version of the CBS investigation.
auto-caption available; no chapters.
Claim-by-claim audit
Review topic: retatrutide marketing.
Checked against: Retatrutide phase 2 results: 24.2% weight loss (NEJM), Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.
Review topic: status.
Checked against: TRIUMPH-1: retatrutide in participants with obesity or overweight, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
Review topic: provider conduct / safety signal.
Checked against: Primary-source record still needed
underlying CBS investigation and primary records.
Review topic: vendor landscape.
Checked against: Primary-source record still needed
archived pages/source packet.
Review topic: enforcement.
Checked against: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss., Warning Letter: Gram Peptides
Source check
Retatrutide phase 2 obesity trial (NEJM 2023): at 12 mg, mean body weight fell 17.5% at week 24 and 24.2% at week 48; GI adverse events were most common.
nejm-retatrutide-phase2-2023Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. News release, 2026-05-21.
research-reta-04Completed Phase 3 master protocol NCT05929066. The registry identifies TRIUMPH-1 as a randomized, double-blind, placebo-controlled study in adults without type 2 diabetes who have obesity or overweight.
clinicaltrials-retatrutide-triumph1U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Accessed 2026-07-12.
research-reta-02FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
fda-gram-peptides-warning-2026